<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006749.pub3" GROUP_ID="ADDICTN" ID="047306011015313707" MERGED_FROM="" MODIFIED="2014-04-28 11:12:13 +0100" MODIFIED_BY="Laura Amato" REVIEW_NO="43" REVMAN_SUB_VERSION="5.2.11 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2014-04-28 11:59:23 +0200" MODIFIED_BY="Laura Amato" NOTES="&lt;p&gt;&lt;b&gt;H Maxwell:&lt;/b&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;General comments&lt;/b&gt;&lt;br&gt;UK English confirmed, as requested.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Study ID Lists&lt;br&gt;&lt;/b&gt;Alphabetical order.&lt;br&gt;&lt;br&gt;&lt;b&gt;Hyphens&lt;br&gt;&lt;/b&gt;The Cochrane Style Guide recommends that two-word compounds used as adjectives should have a hyphen e.g., long-term treatment (versus in the lon term). Amended as required.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Lists&lt;/b&gt;&lt;br&gt;Formatted lists for consistency&lt;/p&gt;&lt;p&gt;&lt;b&gt;Validation report warnings&lt;/b&gt;&lt;br&gt;There were several warnings (all amended. &lt;i&gt;See&lt;/i&gt; note attached to References&lt;/p&gt;" NOTES_MODIFIED="2014-04-28 11:59:23 +0200" NOTES_MODIFIED_BY="Laura Amato">
<TITLE>Detoxification treatments for opiate dependent adolescents</TITLE>
<CONTACT>
<PERSON ID="6297" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Silvia</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Minozzi</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>minozzi.silvia@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology</DEPARTMENT>
<ORGANISATION>Lazio Regional Health Service</ORGANISATION>
<ADDRESS_1>Via di Santa Costanza, 53</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00198</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-04-28 11:59:23 +0200" MODIFIED_BY="Laura Amato">
<PERSON ID="6297" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Silvia</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Minozzi</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>minozzi.silvia@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology</DEPARTMENT>
<ORGANISATION>Lazio Regional Health Service</ORGANISATION>
<ADDRESS_1>Via di Santa Costanza, 53</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00198</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11445" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Laura</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Amato</LAST_NAME>
<SUFFIX/>
<POSITION>Managing Editor</POSITION>
<EMAIL_1>l.amato@deplazio.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology</DEPARTMENT>
<ORGANISATION>Lazio Regional Health Service</ORGANISATION>
<ADDRESS_1>Via di Santa Costanza, 53</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00198</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+390683060483</PHONE_1>
<PHONE_2/>
<FAX_1>+390683060463</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1306211439345307718635486601132" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Cristina</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bellisario</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>cristina.bellisario@cpo.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>CPO Piemonte, Dipartimento Interaziendale di Prevenzione Secondaria dei Tumori S.C. Epidemiologia dei Tumori</DEPARTMENT>
<ORGANISATION>AO Città della Salute e della Scienza di Torino Via San Francesco da Paola 31</ORGANISATION>
<ADDRESS_1>Via San Francesco da Paola 31</ADDRESS_1>
<ADDRESS_2/>
<CITY>Torino</CITY>
<ZIP>10123</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+390116333879</PHONE_1>
<PHONE_2/>
<FAX_1>+390116333886</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6213" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Marina</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Davoli</LAST_NAME>
<SUFFIX/>
<POSITION>Coordinating Editor</POSITION>
<EMAIL_1>m.davoli@deplazio.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology</DEPARTMENT>
<ORGANISATION>Lazio Regional Health Service</ORGANISATION>
<ADDRESS_1>Via di Santa Costanza, 53</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00199</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 06 83060 444</PHONE_1>
<PHONE_2/>
<FAX_1>+39 06 83060463</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-04-10 09:36:54 +0200" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="10" MONTH="4" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="1" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="10" MONTH="4" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-04-28 11:44:45 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;b&gt;H Maxwell:&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;What&amp;#8217;s new&lt;br&gt;&lt;/b&gt;Does not mention that an additional 11 studies were excluded.&lt;/p&gt;" NOTES_MODIFIED="2014-04-28 11:44:45 +0200" NOTES_MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-04-28 11:44:45 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="4" YEAR="2014"/>
<DESCRIPTION>
<P>No new studies included.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-04-28 11:44:37 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="4" YEAR="2014"/>
<DESCRIPTION>
<P>New search. Backround updated, 'Summary of findings' tables created.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-04-10 09:37:02 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-04-10 09:37:02 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="7" YEAR="2009"/>
<DESCRIPTION>
<P>We emended the abstract's errors</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-02-16 11:13:09 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="2" YEAR="2009"/>
<DESCRIPTION>
<P>to be published as review in the issue 2, 2009</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-02-16 11:13:19 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>stage changed in review</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-02-16 11:13:24 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="3" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_MAJOR">
<DATE DAY="27" MONTH="6" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-03-20 16:37:10 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2008-03-20 16:37:10 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-03-20 16:37:10 +0100" MODIFIED_BY="[Empty name]">
<NAME>Department of Epidemiology, ASL RM E</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-04-28 11:57:49 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-04-28 11:53:10 +0200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-01-26 10:47:29 +0100" MODIFIED_BY="[Empty name]">Detoxification treatments for opiate dependent adolescents</TITLE>
<SUMMARY_BODY MODIFIED="2014-04-28 11:53:10 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Detoxification treatment for heroin dependents adolescents</B>
</P>
<P>
<B>Review question</B>
</P>
<P>We reviewed the evidence on the effect of detoxification treatment compared with pharmacological maintenance treatment or psychosocial intervention in achieving abstinence on adolescents heroin dependents.
</P>
<P>
<B>Background</B>
</P>
<P>Substance abuse among adolescents (13 to 18 years old) is a serious and growing problem. It is important to identify effective treatments for those who are opioid dependent. For adults, pharmacotherapy is a necessary and acceptable part of effective treatment. Detoxification agents are used to reduce withdrawal symptoms during managed withdrawal but the rate of completion of detoxification tends to be low, and rates of relapse are high. Withdrawal symptoms, particularly drug craving, may continue for weeks and even months after detoxification. The period of recovery from dependence is typically influenced by a range of psychological, social and treatment-
related factors. Detoxification treatments include methadone, buprenorphine, and alpha2-adrenergic agonists.</P>
<P>
<B>Study characteristics</B>
</P>
<P>The review authors searched the literature for randomised controlled trials investigating pharmacological interventions with or without psychosocial intervention aimed at detoxification in adolescents. They found only two trials, both conducted in the USA; one compared 28-day treatment with buprenorphine, using tablets placed under the tongue, to wearing a clonidine patch in 36 opiate dependent adolescents who were treated as outpatients. The other trial compared maintenance treatment versus detoxification treatment: buprenorphine-naloxone maintenance versus buprenorphine detoxification.</P>
<P>
<B>Key results</B>
</P>
<P>The trial comparing buprenorphine with clonidine reported a trend in favour of buprenorphine in reducing the drop-out rate but no difference between treatments in the duration and severity of withdrawal symptoms. More participants in the buprenorphine group went on to long-term naltrexone treatment. Side effects were not reported. In the second trial comparing buprenorphine maintenance versus buprenorphine for detoxification, for drop out the results were in favour of maintenance treatment, At one-year follow-
up, self-reported opioid use was clearly less in the maintenance group and more adolescents were enrolled in other addiction programs. Conducting trials with young people may be difficult for both practical and ethical reasons.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>This review was limited by the very few number of trials retrieved and the quality of the evidence was moderate for the comparison between buprenorphine and clonidine and low for the comparison between buprenorphine detoxification and buprenorphine maintenance. The evidence is current to January 2014.
<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-04-28 11:52:57 +0200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-04-28 11:51:16 +0200" MODIFIED_BY="[Empty name]">
<P>The scientific literature examining effective treatments for opioid dependent adults clearly indicates that pharmacotherapy is a necessary and acceptable component of effective treatments for opioid dependence. Nevertheless, no studies have been published that systematically assess the effectiveness of the pharmacological detoxification among adolescents.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-04-28 11:51:20 +0200" MODIFIED_BY="[Empty name]">
<P>To assess the effectiveness of any detoxification treatment alone or in combination with psychosocial intervention compared with no intervention, other pharmacological intervention or psychosocial interventions on completion of treatment, reducing the use of substances and improving health and social status.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-04-28 11:51:27 +0200" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (2014, Issue 1), PubMed (January 1966 to January 2014), EMBASE (January 1980 to January 2014), CINHAL (January 1982 to January 2014), Web of Science (1991-January 2014) and reference lists of articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-04-28 11:51:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised controlled clinical trials comparing any pharmacological interventions alone or associated with psychosocial intervention aimed at detoxification with no intervention, placebo, other pharmacological intervention or psychosocial intervention in adolescents (13 to 18 years).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-04-28 11:51:45 +0200" MODIFIED_BY="[Empty name]">
<P>We used standard methodological procedures recommended by The Cochrane Collaboration</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-04-28 11:52:43 +0200" MODIFIED_BY="[Empty name]">
<P>Two trials involving 190 participants were included. One trial compared buprenorphine with clonidine for detoxification. No difference was found for drop out: risk ratio (RR) 0.45 (95% confidence interval (CI): 0.20 to 1.04) and acceptability of treatment: withdrawal score mean difference (MD): 3.97 (95% CI -1.38 to 9.32). More participants in the buprenorphine group initiated naltrexone treatment: RR 11.00 (95% CI 1.58 to 76.55), quality of evidence moderate.</P>
<P>The other trial compared maintenance treatment versus detoxification treatment: buprenorphine-naloxone maintenance versus buprenorphine detoxification. For drop out the results were in favour of maintenance treatment: RR 2.67 (95% CI 1.85, 3.86), as well as for results at follow-up RR 1.36 [95% CI 1.05to 1.76); no differences for use of opiate, quality of evidence low.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-04-28 11:52:49 +0200" MODIFIED_BY="[Empty name]">
<P>It is difficult to draw conclusions on the basis of two trials with few participants. Furthermore, the two studies included did not consider the efficacy of methadone that is still the most frequent drug utilised for the treatment of opioid withdrawal. One possible reason for the lack of evidence could be the difficulty in conducting trials with young people due to practical and ethical reasons.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-04-28 11:57:49 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-04-28 11:53:41 +0200" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2014-04-28 11:53:18 +0200" MODIFIED_BY="[Empty name]">
<P>Several studies have demonstrated that adolescent (less than 18 years old) substance abuse is a serious and growing problem (<LINK REF="REF-Altobelli-2005" TYPE="REFERENCE">Altobelli 2005</LINK>).</P>
<P>In Europe, the estimate of lifetime prevalence of use for young adults 15 to 34 years old is of 32.5% for cannabis, 6.3 % for cocaine, ranging from 0.7 % to 13.6 % in different countries, 5.5 % for amphetamines, ranging from under 0.6 % to 12.4 %; most countries reported estimates in the range of 2.1 to 5.8 % for ectasy and from 0.1 % to 5.4 % for LSD. National estimates vary widely between countries in all measures of prevalence. Opioids, mainly heroin, were cited as the primary drug by more than 200,000 clients reported entering specialist drug treatment in 29 European countries in 2010, or 48 % of all reported treatment entrants (<LINK REF="REF-EMCDDA-2012" TYPE="REFERENCE">EMCDDA 2012</LINK>).</P>
<P>In Europe in 2011, the European School Survey Project on Alcohol and Other Drugs (ESPAD) collected data on substance use of more than 100,000 15 to 16-year-old European students from 36 countries. Nearly one in three (29%) students in the ESPAD countries perceived cannabis to be (fairly or very) easily available. On average, 18% of students have tried illicit drugs at least once during their lifetime. Most of them (17%) have used cannabis while 6% reported experience with drugs other than cannabis. After cannabis, amphetamines and ecstasy are in second position, each being mentioned by 3% of the students. Lifetime use of cocaine, crack and LSD or other hallucinogens was reported by fewer students (2%) and the rates for heroin and GHB were even lower (1%). Use of cannabis in the past 12 months was 13%, while use in the past 30 days was claimed to be 7% (<LINK REF="REF-ESPAD-2012" TYPE="REFERENCE">ESPAD 2012</LINK>).</P>
<P>In the USA, recent household survey data indicate 9.5 % of youths aged 12 to 17 were current illicit drug users. This rate was similar to the rates of current illicit drug use in 2005 to 2011, but it was lower than the rates from 2002 to 2004. In addition, 7.2 % of youths aged 12 to 17 were current users of marijuana, 2.8 % were current non medical users of psychotherapeutic drugs, 0.8 % were current users of inhalants, 0.6% were current users of hallucinogens, and 0.1 % were current users of cocaine (<LINK REF="REF-SAMHSA-2013" TYPE="REFERENCE">SAMHSA 2013</LINK>).</P>
<P>In the USA after 1992, the proportion of young Americans with lifetime use of any drugs rose considerably to a recent high point of 55% in 1999; it then declined gradually to 47% in 2007 through 2009, and stands at 49% in 2012. The annual prevalence of heroin use among 12<SUP>th</SUP> graders fell by half between 1975 and 1979, from 1.0% to 0.5%. The rate then held amazingly steady until 1994. Use rose in the mid and late 1990s, along with the use of most drugs; it reached peak levels in 1996 among 8th graders (1.6%), in 1997 among 10<SUP>th</SUP> graders (1.4%), and in 2000 among 12th graders (1.5%), suggesting a cohort effect. Since those peak levels, use has declined, with annual prevalence in all three grades fluctuating between 0.7% and 0.9% from 2005 through 2011. Use has declined some in the past two years; in the three grades combined, the 2011 to 2012 decline from 0.7% to 0.6% was significant (<LINK REF="REF-Monitoring-the-Future-2013" TYPE="REFERENCE">Monitoring the Future 2013</LINK>).</P>
<P>In 2010, most Australians aged 14 years and over (60%) had never used an illicit drug. However, around 15% had used one or more illicit drugs in the past 12 months. Cannabis was the most common illicit drug used recently (10.3%), followed by ecstasy (3.0%) and amphetamines and cocaine (each used by 2.1% of people). Many people who used an illicit drug in 2010 also used other drugs, illicit or licit ( <LINK REF="REF-AIHW-2011" TYPE="REFERENCE">AIHW 2011</LINK>).</P>
<P>Patterns of drug use have changed over time. An analysis of treatment entry data between 2000 and 2009 showed a decrease in drug injection among primary heroin clients in all European countries (from 58 % to 36 %), particularly in western Europe (<LINK REF="REF-EMCDDA-2012" TYPE="REFERENCE">EMCDDA 2012</LINK>). In addition, among opioid users entering treatment in outpatient settings since 2009, those smoking the drug outnumbered those injecting it (<LINK REF="REF-EMCDDA-2012" TYPE="REFERENCE">EMCDDA 2012</LINK>).
</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-04-28 11:53:36 +0200" MODIFIED_BY="[Empty name]">
<P>Numerous medications have been successfully used in the treatment of adolescents with a broad array of psychiatric disorders (<LINK REF="REF-Hunt-1990" TYPE="REFERENCE">Hunt 1990</LINK>; <LINK REF="REF-Kaminer-1995" TYPE="REFERENCE">Kaminer 1995</LINK>). In contrast, medications have been infrequently used in treating substance abuse disorders among adolescents, nevertheless they have generally been shown to be a promising component of such interventions (<LINK REF="REF-Kaminer-1995" TYPE="REFERENCE">Kaminer 1995</LINK>).<BR/>
<BR/>The scientific literature examining effective treatments for opioid dependent adults clearly indicates that pharmacotherapy is a necessary and acceptable component of effective treatments for opioid dependence. Nevertheless, when young people must be treated, it probably is necessary to monitor the interventions in order to adapt them to this specific population. Different pharmacological agents have been used as detoxification agents to ameliorate withdrawal symptoms, however, the rate of completion of detoxification tends to be low, and rates of relapse to opioid use following detoxification are high (<LINK REF="REF-Gossop-1989" TYPE="REFERENCE">Gossop 1989</LINK>; <LINK REF="REF-Vaillant-1988" TYPE="REFERENCE">Vaillant 1988</LINK>). Methadone may still be the medication that is most widely used but buprenorphine is seen as having some advantages for adolescents because of its excellent safety profile and the absence of long-term complications (<LINK REF="REF-Levy-2007" TYPE="REFERENCE">Levy 2007</LINK>; <LINK REF="REF-Smith-2012" TYPE="REFERENCE">Smith 2012</LINK>). Younger patients who present for treatment of drug dependence often have a shorter history of drug use than treatment-seeking adults. Treatment early in the course of the disorder presents the opportunity to prevent co-morbidities associated with drug use, including acute and chronic medical conditions, and psychiatric and social complications (<LINK REF="REF-Levy-2007" TYPE="REFERENCE">Levy 2007</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2014-04-26 17:23:10 +0200" MODIFIED_BY="Heather Maxwell">
<P>Managed withdrawal, or detoxification, is not in itself a treatment for dependence (<LINK REF="REF-Lipton-1983" TYPE="REFERENCE">Lipton 1983</LINK>; <LINK REF="REF-Mattick-1996" TYPE="REFERENCE">Mattick 1996</LINK>) but detoxification remains a required first step for many forms of longer-term treatment (<LINK REF="REF-Kleber-1982" TYPE="REFERENCE">Kleber 1982</LINK>). Withdrawal symptoms, particularly drug craving, may continue to be experienced for weeks and even for months after detoxification, and the period of recovery from dependence is typically influenced by a range of psychological, social and treatment-
related factors.</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-04-28 11:53:41 +0200" MODIFIED_BY="[Empty name]">
<P>We did not find any reviews in the published literature that assessed the effectiveness of detoxification treatment for adolescents. Many other Cochrane systematic reviews have been published on the effectiveness of various detoxification treatments: methadone (<LINK REF="REF-Amato-2013" TYPE="REFERENCE">Amato 2013</LINK>), buprenorphine (<LINK REF="REF-Gowing-2009" TYPE="REFERENCE">Gowing 2009</LINK>), alpha2-adrenergic agonists (<LINK REF="REF-Gowing-2014" TYPE="REFERENCE">Gowing 2014</LINK>), opioid antagonists with minimal sedation (<LINK REF="REF-Gowing-2009b" TYPE="REFERENCE">Gowing 2009b</LINK>) and under heavy sedation (<LINK REF="REF-Gowing-2010" TYPE="REFERENCE">Gowing 2010</LINK>), psychosocial combined with detoxification treatment (<LINK REF="REF-Amato-2011" TYPE="REFERENCE">Amato 2011</LINK>) and one review comparing inpatient versus outpatient settings for opioid detoxification (<LINK REF="REF-Day-2005" TYPE="REFERENCE">Day 2005</LINK>), but none address the question of the effectiveness of treatments for adolescents.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-04-28 11:53:53 +0200" MODIFIED_BY="[Empty name]">
<P>To assess the effectiveness of any detoxification treatment alone or in combination with psychosocial intervention compared with no intervention, other pharmacological intervention or psychosocial interventions on completion of treatment, reducing the use of substances and improving health and social status.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-04-28 11:55:24 +0200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-04-28 11:54:12 +0200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2014-04-28 11:53:46 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) and controlled clinical trials (CCTs).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-04-28 11:53:57 +0200" MODIFIED_BY="[Empty name]">
<P>Opiate dependent adolescents (13 to 18 years of age). There was no restriction for participants with physical or psychological illness.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-04-28 11:54:02 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental intervention
</B>
<BR/>
</P>
<UL>
<LI>Any pharmacological interventions (methadone, buprenorphine, adrenergic agonists, symptomatics) alone or associated with psychosocial intervention aimed at detoxification</LI>
</UL>
<P>
<B>Control intervention
</B>
<BR/>
</P>
<UL>
<LI>No intervention
</LI>
<LI>Other pharmacological interventions</LI>
<LI>Psychosocial interventions alone</LI>
</UL>
<P>
<B>Types of comparisons foreseen</B>
<BR/>
</P>
<UL>
<LI>Any detoxification treatment versus no treatment</LI>
<LI>Any detoxification treatment versus other pharmacological treatment (e.g. methadone versus buprenorphine)</LI>
<LI>Any pharmacological treatment plus psychosocial treatment versus any pharmacological treatment alone</LI>
<LI>Any detoxification treatment versus any psychosocial treatment</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-04-28 11:54:12 +0200" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-04-28 11:54:08 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Drop outs measured as number of participants who did not complete the detoxification treatment.</LI>
<LI>Use of primary substance measured as number of participants with opiate positive urine analysis during and at the end of treatment or self-reported data.</LI>
<LI>Acceptability of the treatment as A) duration and severity of signs and symptoms of withdrawal, including patient self-rating B) side effects.</LI>
<LI>Results at follow-up measured as number of participants who relapsed at the end of follow-up.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-04-28 11:54:12 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Engagement in further treatment measured as number of participants who enrolled in any psychosocial or pharmacological treatment.</LI>
<LI>Use of other substances of abuse.</LI>
<LI>Overdose, fatal or nonfatal.</LI>
<LI>Criminal activity.</LI>
<LI>Social functioning (integration at school or at work, family relationship).
</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-04-28 11:54:18 +0200" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2014-04-26 17:27:39 +0200" MODIFIED_BY="Heather Maxwell">
<P>For this update, we revised the search strategy and re-ran searches in the following databases.

</P>
<OL>
<LI>Cochrane Drugs and Alcohol Group's trials register (Jannuary 2014).

</LI>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2014, Issue 1).

</LI>
<LI>MEDLINE (PubMed) (from 1966 - to Jannuary 2014).

</LI>
<LI>EMBASE (embase.com) (from 1980 - to Jannuary 2014).

</LI>
<LI>CINAHL (EBSCO) (1982 - to Jannuary 2014).

</LI>
<LI>Web of Science (1991 - to Jannuary 2014).</LI>
</OL>
<P>Databases were searched using a strategy developed by incorporating the filter for identification of RCTs (<A HREF="http://archie.cochrane.org/sections/documents/view?document=24966510546232883670100218132311&amp;format=REVMAN#REF-Lefebvre-2011">Lefebvre 2011</A>) combined with selected MeSH terms and free-text terms related to alcohol dependence. For details on searches<I> see </I>
<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>; <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>; <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>
.
</P>
<P>We also searched some of the main electronic sources of ongoing trials.

<BR/>
</P>
<OL>
<LI>Current Controlled Trials (www.controlled-trials.com/).</LI>
<LI>Clinical Trials.gov (www.clinicaltrials.gov/).</LI>
<LI>International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/en).</LI>
</OL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-04-28 11:54:18 +0200" MODIFIED_BY="[Empty name]">
<P>We also searched the following.</P>
<OL>
<LI>References of the articles obtained by any means.</LI>
<LI>Conference proceedings likely to contain trials relevant to the review (Annual Scientific Meeting of the College on Problems of Drug Dependence, European College of Neuropsychopharmacology, American Psychiatric Association).</LI>
<LI>By contacting investigators, and relevant trial authors seeking information about unpublished or incomplete trials.</LI>
</OL>
<P>All searches included non-English language literature and studies with English abstracts were assessed for inclusion. When considered likely to meet inclusion criteria, studies were translated.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-04-28 11:55:24 +0200" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2014-04-28 11:54:25 +0200" MODIFIED_BY="[Empty name]">
<P>Two review authors (SM, CB) independently inspected the search 'hits' by reading titles and abstracts. Each potentially relevant study located in the search was obtained in full text and assessed for inclusion independently by two review authors (SM, LA). Any disagreements were resolved by discussion between the authors.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-04-28 11:54:29 +0200" MODIFIED_BY="[Empty name]">
<P>Three review authors (SM, LA, CB) independently extracted data. Any disagreements were discussed and resolved by consensus.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-04-28 11:54:35 +0200" MODIFIED_BY="[Empty name]">
<P>We changed the criteria to assess methodological quality of included studies from that outlined in the protocol to conform the review to the recommended methods outlined in the <I>Cochrane Reviewers Handbook </I>version 5.0.0 and to the requirements of RevMan5 (<LINK REF="REF-Cochrane-Handboook-2008" TYPE="REFERENCE">Cochrane Handboook 2008</LINK>).</P>
<P>The recommended approach for assessing risk of bias in studies included in Cochrane Review is a two-part tool, addressing six specific domains (namely sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting and other issues). The first part of the tool involves describing what was reported to have happened in the study. The second part of the tool involves assigning a judgement relating to the risk of bias for that entry. This is achieved by answering a pre-specified question about the adequacy of the study in relation to the entry, such that a judgement of "Yes" indicates low risk of bias, "No" indicates high risk of bias, and "Unclear" indicates unclear or unknown risk of bias. To make these judgments we used the criteria indicated by the handbook and their applicability in the addiction field. For a detailed description of the criteria used see <LINK REF="REF-Cochrane-Handboook-2008" TYPE="REFERENCE">Cochrane Handboook 2008</LINK>.</P>
<P>The domains of sequence generation, allocation concealment (avoidance of selection bias) and selective outcome reporting (avoidance of reporting bias) have been addressed in the tool by a single entry for each study.</P>
<P>Blinding of participants, personnel and outcome assessors (avoidance of performance bias and detection bias) was considered separately for objective outcomes (drop out, use of substance of abuse measured by urine-analysis, subjects relapsed at the end of follow up, subjects engaged in further treatments) and subjective outcomes (duration and severity of signs and symptoms of withdrawal, including patient self-rating, side effects, social functioning as integration at school or at work, family relationships).</P>
<P>Incomplete outcome data (avoidance of attrition bias) were considered for all outcomes except for drop out from the treatment, which is very often the primary outcome measure in trials on addiction. It have been assessed separately for results at the end of the study period and for results at follow up.</P>
<P>For drop out from treatment we judged that only sequence generation and allocation concealment could be relevant because lack of blinding is unlikely to influence data collection and incomplete outcome data could not be used for this outcome. For use of substances assessed by urine analysis we judged that sequence generation, allocation concealment and incomplete outcome data could influence results. For subjective outcomes we judged that also lack of blinding of outcome assessor could influence data.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-04-28 11:54:43 +0200" MODIFIED_BY="[Empty name]">
<P>Dichotomous outcomes were analysed calculating the risk ratio (RR) for each trial with the uncertainty in each result being expressed by their confidence intervals (CIs). Continuous outcomes were analysed calculating the mean difference (MD), again with 95% CIs.</P>
<P>The drop out from treatment was reported as the number of participants who did not complete the detoxification treatment. The use of primary substance was reported as the number of participants with opiate positive urine analysis during and at the end of treatment, or self-report data.The results at follow-up were measured as number of participants who had relapsed at the end of follow-up. We did not use data presented as number of positive urine tests over total number of tests in the experimental and control group as a measure of substance abuse. This is because using the number of tests instead of the number of participants as the unit of analysis violates the hypothesis of independence among observations. In fact, the results of tests done in each participant are not independent. For outcomes assessed by scales, we compared and pooled the mean score differences from the end of treatment to baseline (post minus pre) in the experimental and control group. In case of missing data about the standard deviation of the change, we imputed this measure using the standard deviation at the end of treatment for each group.</P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-04-28 11:54:47 +0200" MODIFIED_BY="[Empty name]">
<P>Heterogeneity was analysed by means of the I<SUP>2</SUP> statistic and Chi<SUP>2</SUP> test for heterogeneity.The cut-off points were I<SUP>2 </SUP>&gt; 50% and P of the Chi<SUP>2</SUP> test &lt; 0.1.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-04-26 17:30:18 +0200" MODIFIED_BY="Heather Maxwell">
<P>We planned to use funnel plots (plots of the effect estimate from each study against the sample size or effect standard error) to assess the potential for bias related to the size of the trials, which could indicate possible publication bias, but did not as we included only two trials.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-04-28 11:55:03 +0200" MODIFIED_BY="[Empty name]">
<P>We planned to combine the relative risk (RR) or the weighted mean difference (WMD) from the individual trials through meta-analysis where possible (comparability of intervention and outcomes between trials) using a random-effects model as some variability was expected in the studies included. We included only two trials with different comparisons, which prevented the possibility of performing meta-analysis. Accordingly, we used a fixed-effect method with risk ratio (RR) for dichotomous data and mean difference (MD) for continuous data..</P>
</DATA_SYNTHESIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-04-28 11:55:24 +0200" MODIFIED_BY="[Empty name]">
<P>To incorporate assessment of risk of bias in the review process, we planned to first plot intervention effects estimates stratified for risk of bias for each relevant domain. If differences in results were present among studies at different risk of bias, we planned to perform sensitivity analysis excluding from the analysis studies with a high risk of bias. This was not done because only one study was included in each comparison of the review.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-04-28 11:57:01 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-04-28 11:55:48 +0200" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2014-04-28 11:55:32 +0200" MODIFIED_BY="[Empty name]">
<P>This is an update of a Cochrane review first published in 2009. In the first version of our review we identified 2917 references. After excluding duplicate articles, we identified 2595 potentially relevant references. We excluded 2586 on the basis of title and abstracts leaving 10 studies which were acquired in full text for more evaluation. Out of these, seven studies were excluded, one was included, one is an ongoing trial and one study was classified as study awaiting assessment because it is finished but not yet published and the authors could not give us the data. Immediately before the publication of the review (November 2008) the ongoing study was published, so we decided to include it. See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<P>In the 2014 update, we retrieved 1004 further references after excluding duplicates. We further excluded 986 articles on the basis of title and abstract and 15 were acquired in full text for more detailed evaluation. Out of the 15 studies, two (Woody 2009 and Woody 2013) were errata corrige of <LINK REF="STD-Woody-2008" TYPE="STUDY">Woody 2008</LINK>. One study (with two conference proceedings) was classified as awaiting classification because although the study is finished, it is not yet published and the authors could not give us the data (<LINK REF="STD-Marsh-2009" TYPE="STUDY">Marsh 2009</LINK>).The other 11 retrieved studies were excluded. See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<P>For substantive descriptions of studies <I>see</I> <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables.
</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-04-28 11:55:39 +0200" MODIFIED_BY="[Empty name]">
<P>Two studies met the inclusion criteria (<LINK REF="STD-Marsch-2005" TYPE="STUDY">Marsch 2005</LINK>; <LINK REF="STD-Woody-2008" TYPE="STUDY">Woody 2008</LINK>). No further studies were retrieved for inclusion in the 2014 update.</P>
<UL>
<LI>
<B>Type of comparison</B>: buprenorphine sublingual tablets versus clonidine patch (<LINK REF="STD-Marsch-2005" TYPE="STUDY">Marsch 2005</LINK>; buprenorphine-naloxone maintenance versus buprenorphine detox (<LINK REF="STD-Woody-2008" TYPE="STUDY">Woody 2008</LINK>)</LI>
<LI>
<B>Participants</B>: 190 opiate dependent adolescents (13 to 21 years old)</LI>
<LI>
<B>Duration of the trial</B>: 28 days (<LINK REF="STD-Marsch-2005" TYPE="STUDY">Marsch 2005</LINK>); 12 weeks (<LINK REF="STD-Woody-2008" TYPE="STUDY">Woody 2008</LINK>)</LI>
<LI>
<B>Setting:</B> outpatients</LI>
<LI>
<B>Country</B>: USA</LI>
</UL>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-04-28 11:55:48 +0200" MODIFIED_BY="[Empty name]">
<P>Overall, 18 studies did not meet the criteria for inclusion in this review. The grounds for exclusion were: study design not in the inclusion criteria: not RCT or CCT: five studies (<LINK REF="STD-Ebner-2007" TYPE="STUDY">Ebner 2007</LINK>; <LINK REF="STD-Fiellin-2008" TYPE="STUDY">Fiellin 2008</LINK>; <LINK REF="STD-Godley-2004" TYPE="STUDY">Godley 2004</LINK>; <LINK REF="STD-Lloyd-1974" TYPE="STUDY">Lloyd 1974</LINK>; <LINK REF="STD-Moore-2014" TYPE="STUDY">Moore 2014</LINK>); experimental intervention not in the inclusion criteria: only psychosocial intervention without pharmacological detoxification: two studies (<LINK REF="STD-Baer-2007" TYPE="STUDY">Baer 2007</LINK>; <LINK REF="STD-Kemp-2007" TYPE="STUDY">Kemp 2007</LINK>); maintenance treatment: one study (<LINK REF="STD-Lehmann-1973" TYPE="STUDY">Lehmann 1973</LINK>); different psychosocial intervention given to two groups receiving the same pharmacological intervention: one study (<LINK REF="STD-Forcehimes-2008" TYPE="STUDY">Forcehimes 2008</LINK>); outcome not in the inclusion criteria: six studies (<LINK REF="STD-Chakrabarti-2010" TYPE="STUDY">Chakrabarti 2010</LINK>, <LINK REF="STD-Hill-2013" TYPE="STUDY">Hill 2013</LINK>, <LINK REF="STD-Polsky-2010" TYPE="STUDY">Polsky 2010</LINK>; <LINK REF="STD-Subramaniam-2011" TYPE="STUDY">Subramaniam 2011</LINK>; <LINK REF="STD-Warden-2012" TYPE="STUDY">Warden 2012</LINK>; <LINK REF="STD-Wilcox-2013" TYPE="STUDY">Wilcox 2013</LINK>); participant not in the inclusion criteria: one study (<LINK REF="STD-Mannelli-2011" TYPE="STUDY">Mannelli 2011</LINK>); study design and participants not in the inclusion criteria: one study (<LINK REF="STD-Mullen-2010" TYPE="STUDY">Mullen 2010</LINK>); secondary analysis of the <LINK REF="STD-Marsch-2005" TYPE="STUDY">Marsch 2005</LINK> study without distinction between experimental and control condition (<LINK REF="STD-Moore-2011" TYPE="STUDY">Moore 2011</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-04-28 11:55:59 +0200" MODIFIED_BY="[Empty name]">
<P>see <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>
</P>
<ALLOCATION MODIFIED="2014-04-28 11:55:59 +0200" MODIFIED_BY="[Empty name]">
<P>Sequence generation and allocation concealment: we judged one study as at unclear risk of bias (<LINK REF="STD-Marsch-2005" TYPE="STUDY">Marsch 2005</LINK>). The other study (<LINK REF="STD-Woody-2008" TYPE="STUDY">Woody 2008</LINK>) was judged to be at low risk of bias for sequence generation and at high risk of bias for allocation concealment.</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-04-28 11:55:54 +0200" MODIFIED_BY="[Empty name]">
<P>Both studies were judged to be at a low risk of bias for objective outcomes. For subjective outcomes, one study (<LINK REF="STD-Marsch-2005" TYPE="STUDY">Marsch 2005</LINK>) was judged at low risk of bias, whereas the other (<LINK REF="STD-Woody-2008" TYPE="STUDY">Woody 2008</LINK>), was judged to be at a high risk of bias.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2009-02-05 15:27:41 +0100" MODIFIED_BY="[Empty name]">
<P>Both studies were judged as at low risk of bias. </P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2009-02-05 15:27:52 +0100" MODIFIED_BY="[Empty name]">
<P>Both studies were judged as at low risk of bias.</P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-04-28 11:57:01 +0200" MODIFIED_BY="[Empty name]">
<P>No meta-analysis was performed because the two studies assessed different comparisons.</P>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1: any detoxification treatment versus other pharmacological treatment: buprenorphine versus clonidine</HEADING>
<P>See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>
</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>
<B>Drop out from treatment:</B> risk ratio (RR): 0.45 (95% confidence interval (CI): 0.20 to 1.04); the result is not statistically significant but there is a trend in favour of buprenorphine. See <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.</P>
<P>
<B>Acceptability of the treatment:</B>
</P>
<UL>
<LI>
<B>duration and severity of signs and symptoms of withdrawal:</B> Adjective rating scale: mean difference (MD): 3.97 (95% CI -1.38 to 9.32); the result is not statistically significant. See <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.</LI>
<LI>
<B>side effects:</B> side effects were not reported in the study.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>
<B>Engagement in further treatment:</B> measured as the number of participants who enrolled in any psychosocial or pharmacological treatment: initiation of naltrexone treatment: RR 11.00 (95% CI 1.58 to 76.55); the result is in favour of buprenorphine. See <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>.<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 2: maintenance treatment versus detoxification treatment: buprenorphine-naloxone maintenance for nine weeks then tapered to 12 weeks versus buprenorphine detoxification 14 days</HEADING>
<P>See <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>
</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<UL>
<LI>
<B>Drop out from treatment:</B> RR 2.67 (95% CI 1.85 to 3.86); in favour of maintenance treatment. See <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>.</LI>
<LI>
<B>Use of substance of abuse:</B> no significant difference. See <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>.</LI>
<LI>
<B>Results at follow-up:</B> self-reported heroin use at 12 months: RR 1.36 (95% CI 1.05 to 1.76); in favour of maintenance treatment. See <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>.</LI>
<LI>
<B>Enrolment in addiction treatment at 12 months:</B> RR: 0.75 (0.53 to 1.07); there is a trend in favour of maintenance treatment. See <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<UL>
<LI>
<B>Use of other substances of abuse:</B> no significant difference for alcohol and marijuana; RR 8.54 (95%CI 1.11 to 65.75); in favour of maintenance treatment. See <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>; <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>; <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>.</LI>
<LI>
<B>Side effects:</B> the authors reported that no serious side effects attributable to buprenorphine-naloxone were reported and no patients were removed from the study for side effects. The most common side effect was headache, which was reported by 16% to 21% of patients in both groups.</LI>
<LI>
<B>Mortality any cause:</B> one death for methadone overdose occurred in the maintenance group in a patient who dropped out after three doses and was not located until her obituary appeared in a newspaper three months later.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-04-28 11:57:37 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2014-04-28 11:57:08 +0200" MODIFIED_BY="[Empty name]">
<P>Despite a comprehensive search of published and unpublished literature only two studies were found. One (<LINK REF="STD-Marsch-2005" TYPE="STUDY">Marsch 2005</LINK>) compared buprenorphine and clonidine for detoxification of adolescents. The study found no difference in drop-out rate and in withdrawal symptoms even if the difference in drop-out rate is nearly significant in favour of buprenorphine. More participants in the buprenorphine group initiated naltrexone treatment. The other study (<LINK REF="STD-Woody-2008" TYPE="STUDY">Woody 2008</LINK>) compared maintenance treatment with buprenorphine-naloxone for nine weeks then tapered until 12 weeks with 14 days detoxification with buprenorphine. Maintenance treatment seems more efficacious in retaining patients in treatment but not in reducing patients with positive urine at the end of the study. Self-reported opioid use at one year follow-up was significantly lower in the maintenance group even if both groups reported high level of opioid use and more patients in the maintenance group were enrolled in other addiction treatment at 12-month follow-up.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-04-28 11:57:27 +0200" MODIFIED_BY="[Empty name]">
<P>One study (<LINK REF="STD-Marsch-2005" TYPE="STUDY">Marsch 2005</LINK>) with few participants has too little evidence to draw any conclusions about the superiority of buprenorphine over clonidine. Moreover, there are no studies comparing pharmacological detoxification with psychosocial intervention alone, which is the most used approach to treat opioid dependent adolescents. The study of <LINK REF="STD-Woody-2008" TYPE="STUDY">Woody 2008</LINK> compares a short-term maintenance treatment with a 14-day detoxification. More than a maintenance treatment, the 12 week buprenorphine-naloxone could be considered a long-term detoxification following a two-month stabilisation period. Only one study with 150 participants has too little evidence to draw any firm conclusions.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-04-28 11:57:32 +0200" MODIFIED_BY="[Empty name]">
<P>The quality of evidence was judged as moderate for the comparison between buprenorphine versus clonidine . The main reason for downgrading was due to the fact that only one study with 36 participants was found for this comparison. The quality of evidence was judged as low for the comparison between buprenorphine detoxification versus buprenorphine maintenance The reasons were that there was no allocation concealment, no blinding of participants, personnel and outcome assessor, and because only one trial with 154 participants has been found for this comparison.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-04-28 11:57:37 +0200" MODIFIED_BY="[Empty name]">
<P>A particularly important component of a review is the identification of relevant studies. Publication bias has long been recognised as a problem in this regard since it means that the likelihood of finding studies is related to the results of those studies. One way to investigate whether a review is subject to publication bias is to prepare a &#8216;funnel plot&#8217; and examine this for signs of asymmetry. We could not explore the possibility of publication bias by funnel plot because only two studies was retrieved. We looked for all potentially relevant studies by a comprehensive search, which considered also conference proceedings and registers of ongoing trials. We wrote to the author of the only published trial asking for other trials but she did not answer. We also looked at references of published narrative reviews.</P>
</POTENTIAL_BIASES>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-04-28 11:57:49 +0200" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-04-28 11:57:43 +0200" MODIFIED_BY="[Empty name]">
<P>It is difficult to draw conclusions on the basis of two trials with few participants. One possible reason for the lack of evidence could be the difficulty in conducting trials with young people due to practical and ethical reasons.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-04-28 11:57:49 +0200" MODIFIED_BY="[Empty name]">
<P>There is an urgent need of randomised controlled trials comparing pharmacological detoxification versus psychosocial intervention and trials comparing pharmacological intervention plus psychosocial intervention versus psychosocial intervention alone before realising trials which compare different pharmacological approaches. These studies should have a long follow-up measuring results of relapse after the end of treatment.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-04-25 17:20:25 +0200" MODIFIED_BY="Heather Maxwell">
<P>We want thank Zuzana Mitrova for her help in all the steps of the review process and Simona Vecchi who performed the bibliographic search.
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-04-28 11:39:04 +0200" MODIFIED_BY="[Empty name]">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-04-25 17:20:53 +0200" MODIFIED_BY="Heather Maxwell">
<P>Silvia Minozzi and Cristina Bellisario inspected the search 'hits' by reading titles and abstracts. Silvia Minozzi, Laura Amato and Cristina Bellisario extracted data, Silvia Minozzi wrote the review, Laura Amato commented and drafted conclusions. Marina Davoli commented on the final draft.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-04-28 11:39:01 +0200" MODIFIED_BY="[Empty name]">
<P>We changed the criteria to assess methodological quality of included studies from that described in the protocol to conform to the recommended methods outlined in the <LINK REF="REF-Cochrane-Handboook-2008" TYPE="REFERENCE">Cochrane Handboook 2008</LINK> and to the requirements of RevMan5.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-04-28 11:44:00 +0200" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-04-28 11:44:00 +0200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-04-28 11:34:35 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Marsch-2005" MODIFIED="2014-04-28 11:34:35 +0200" MODIFIED_BY="[Empty name]" NAME="Marsch 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-04-28 11:34:35 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marsch LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, et al</AU>
<TI>Comparison of pharmacological treatments for opioid-dependent adolescents</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2005</YR>
<VL>62</VL>
<NO>10</NO>
<PG>1157-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woody-2008" MODIFIED="2014-04-28 11:34:26 +0200" MODIFIED_BY="[Empty name]" NAME="Woody 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-03-25 11:20:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, et al</AU>
<TI>Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth</TI>
<SO>JAMA</SO>
<YR>2008</YR>
<VL>300</VL>
<NO>17</NO>
<PG>2003-11</PG>
<IDENTIFIERS MODIFIED="2014-03-25 11:20:35 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-28 11:34:19 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woody GE</AU>
<TI>Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial (Errata corrige)</TI>
<SO>JAMA</SO>
<YR>2009</YR>
<VL>301</VL>
<NO>8</NO>
<PG>830</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-28 11:34:26 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woody GE</AU>
<TI>Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial (Errata corrige)</TI>
<SO>JAMA</SO>
<YR>2013</YR>
<VL>319</VL>
<NO>14</NO>
<PG>1461</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-04-28 11:35:33 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Baer-2007" MODIFIED="2008-10-17 18:16:52 +0200" MODIFIED_BY="[Empty name]" NAME="Baer 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-10-17 18:16:52 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baer JS, Garret SB, BeadnellB, Wells EA, Peterson PL</AU>
<TI>Brief motivational intervention with homeless adolescents: evaluating effects on substance use and service utilization</TI>
<SO>Psychology of Addictive Behaviors</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>4</NO>
<PG>582-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chakrabarti-2010" MODIFIED="2014-04-28 11:34:45 +0200" MODIFIED_BY="[Empty name]" NAME="Chakrabarti 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-04-28 11:34:45 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chakrabarti A, Woody GE, Griffin ML, Subramaniam G, Weiss RD</AU>
<TI>Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2010</YR>
<VL>107</VL>
<NO>2-3</NO>
<PG>253-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ebner-2007" MODIFIED="2014-04-28 11:34:52 +0200" MODIFIED_BY="[Empty name]" NAME="Ebner 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-04-28 11:34:52 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ebner R, Zierer C, Schreiber W</AU>
<TI>After detoxification is before detoxification? Long term outcome of drug dependent adolescent</TI>
<TO>Nach dem Entzug=vor demEntzug? Langzeitvrlauf bei drogenabhangigen Jugendlichen</TO>
<SO>Psychiatrische Praxis</SO>
<YR>2007</YR>
<VL>34</VL>
<NO>Suppl 1</NO>
<PG>s42-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fiellin-2008" MODIFIED="2014-04-03 10:05:50 +0200" MODIFIED_BY="[Empty name]" NAME="Fiellin 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-04-03 10:05:50 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fiellin DA</AU>
<TI>Treatment of adolescent opioid dependence: no quick fix</TI>
<SO>JAMA</SO>
<YR>2008</YR>
<VL>300</VL>
<NO>17</NO>
<PG>2057-9</PG>
<IDENTIFIERS MODIFIED="2014-03-25 10:23:09 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Forcehimes-2008" MODIFIED="2008-10-17 18:19:27 +0200" MODIFIED_BY="[Empty name]" NAME="Forcehimes 2008" YEAR="2008">
<REFERENCE MODIFIED="2008-10-17 18:19:27 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Forcehimes AA, Bogenschutz MP, Tonigan JS, Woody GE</AU>
<TI>Impacy of therapeutic alliance on treatment outcome in opioid dependent adolescent and young adult treated with buprenorphine</TI>
<SO>Proceedings of the70th Annual Scientific Meeting of the College on Problems of Drug Dependence</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Godley-2004" MODIFIED="2014-04-28 11:35:02 +0200" MODIFIED_BY="[Empty name]" NAME="Godley 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-04-28 11:35:02 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Godley SH, Dennis ML, Godely MD, Funk RR</AU>
<TI>Thirty-months relapse trajectory cluster groups among adolescents discharged from out-patients treatment</TI>
<SO>Addiction</SO>
<YR>2004</YR>
<VL>99</VL>
<NO>Suppl 2</NO>
<PG>129-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hill-2013" MODIFIED="2014-04-25 12:53:28 +0200" MODIFIED_BY="Heather Maxwell" NAME="Hill 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-04-25 12:53:28 +0200" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hill KP, Bennett HE, Griffin ML, Connery HS, Fitzmaurice GM, Subramaniam G, et al</AU>
<TI>Association of cannabis use with opioid outcomes among opioid-dependent youth</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2013</YR>
<VL>132</VL>
<NO>1-2</NO>
<PG>342-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kemp-2007" MODIFIED="2008-10-17 18:22:06 +0200" MODIFIED_BY="[Empty name]" NAME="Kemp 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-10-17 18:22:06 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kemp R, Harris A, Vurel E, Siharthan T</AU>
<TI>Stop using stuff: trial of a drug and alcohol intervention for young people with comorbid mental illness and drug and alcohol problems</TI>
<SO>Australasian Psychiatry</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>6</NO>
<PG>490-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lehmann-1973" MODIFIED="2008-10-17 18:23:11 +0200" MODIFIED_BY="[Empty name]" NAME="Lehmann 1973" YEAR="1973">
<REFERENCE MODIFIED="2008-10-17 18:23:11 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lehmann WX</AU>
<TI>The use of 1-alpha-acetyl-methadol (LAAM) as compared to methadone in the maintenance and detoxification of young heroin addicts</TI>
<SO>NIDA monograph</SO>
<YR>1973</YR>
<VL>8</VL>
<PG>82-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lloyd-1974" MODIFIED="2014-04-28 11:35:12 +0200" MODIFIED_BY="[Empty name]" NAME="Lloyd 1974" YEAR="1974">
<REFERENCE MODIFIED="2014-04-28 11:35:12 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lloyd RA, Katon RN, DuPont RL</AU>
<TI>Evolution of a treatment approach for young heroin addicts. Comparison of three treatment modalities</TI>
<SO>International Journal of Addiction</SO>
<YR>1974</YR>
<VL>9</VL>
<NO>2</NO>
<PG>229-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mannelli-2011" MODIFIED="2014-04-28 11:35:19 +0200" MODIFIED_BY="[Empty name]" NAME="Mannelli 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-04-28 11:35:19 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mannelli P, Peindl K, Patkar AA, Wu LT, Tharwani HM, Gorelick D A</AU>
<TI>Problem drinking and low-dose naltrexone-assisted opioid detoxification.</TI>
<SO>Journal of Studies on Alcohol and Drugs</SO>
<YR>2011</YR>
<VL>72</VL>
<NO>3</NO>
<PG>507-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moore-2011" MODIFIED="2014-04-28 11:35:27 +0200" MODIFIED_BY="[Empty name]" NAME="Moore 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-04-28 11:35:27 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moore SK, Marsch LA, Badger GJ, Solhkhah R, Hofstein Y</AU>
<TI>Improvement in psychopathology among opioid-dependent adolescents during behavioral-pharmacological treatment</TI>
<SO>Journal of Addiction Medicine</SO>
<YR>2011</YR>
<VL>5</VL>
<NO>4</NO>
<PG>264-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moore-2014" MODIFIED="2014-04-28 11:35:33 +0200" MODIFIED_BY="[Empty name]" NAME="Moore 2014" YEAR="2014">
<REFERENCE MODIFIED="2014-04-28 11:35:33 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moore SK, GuarinoH, and Marsch, L. A.</AU>
<TI>This is not who I want to be:" experiences of opioid-dependent youth before, and during, combined buprenorphine and behavioral treatment</TI>
<SO>Substance Use &amp; Misuse</SO>
<YR>2014</YR>
<VL>49</VL>
<NO>3</NO>
<PG>303-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mullen-2010" MODIFIED="2014-04-25 12:57:39 +0200" MODIFIED_BY="Heather Maxwell" NAME="Mullen 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-04-25 12:57:39 +0200" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mullen L, Keenan E, Barry J, Long J, Mulholland D, Grogan L, et al</AU>
<TI>Factors predicting completion in a cohort of opiate users entering a detoxification programme</TI>
<SO>Irish Journal of Medical Science</SO>
<YR>2010</YR>
<VL>179</VL>
<NO>4</NO>
<PG>569-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Polsky-2010" MODIFIED="2014-04-03 10:15:16 +0200" MODIFIED_BY="[Empty name]" NAME="Polsky 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-04-03 10:15:16 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Polsky D, Glick HA, Yang J, Subramaniam GA, Poole SA, Woody GE</AU>
<TI>Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial</TI>
<SO>Addiction</SO>
<YR>2010</YR>
<VL>105</VL>
<NO>9</NO>
<PG>1616-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Subramaniam-2011" MODIFIED="2014-04-03 10:18:43 +0200" MODIFIED_BY="[Empty name]" NAME="Subramaniam 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-04-03 10:18:43 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Subramaniam GA, Warden D, Minhajuddin A, Fishman MJ, Stitzer ML, Adinoff B, et al</AU>
<TI>Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth</TI>
<SO>Journal of the American Academy of Child and Adolescent Psychiatry</SO>
<YR>2011</YR>
<VL>50</VL>
<NO>11</NO>
<PG>1120-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warden-2012" MODIFIED="2014-04-25 12:58:20 +0200" MODIFIED_BY="Heather Maxwell" NAME="Warden 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-04-25 12:58:20 +0200" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warden D, Subramaniam GA, Carmody T, Woody GE, Minhajuddin A, Poole SA, et al</AU>
<TI>Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth</TI>
<SO>Adaptive Behavior</SO>
<YR>2012</YR>
<VL>37</VL>
<NO>9</NO>
<PG>1046-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilcox-2013" MODIFIED="2014-04-03 10:21:58 +0200" MODIFIED_BY="[Empty name]" NAME="Wilcox 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-04-03 10:21:58 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilcox CE, Bogenschutz MP, Nakazawa M, Woody G</AU>
<TI>Concordance between self-report and urine drug screen data in adolescent opioid</TI>
<SO>Adaptive Behavior</SO>
<YR>2013</YR>
<VL>38</VL>
<NO>10</NO>
<PG>2568-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-04-25 12:59:00 +0200" MODIFIED_BY="Heather Maxwell">
<STUDY DATA_SOURCE="PUB" ID="STD-Marsh-2009" MODIFIED="2014-04-25 12:59:00 +0200" MODIFIED_BY="Heather Maxwell" NAME="Marsh 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-04-25 12:59:00 +0200" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>March L, Moore SK, Solhkhah R, Badger GJ</AU>
<TI>Predictors of outcome in Buprenorphine treatment for opioid-dependent youth</TI>
<SO>Proceedings of the 71th Annual Scientific Meeting of the College on Problems of Drug Dependence; 2009 June 20-25; Reno/Sparks, Nevada, USA</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 10:23:29 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Marsch LA, MooreS, Solhkhah R</AU>
<TI>A randomized, controlled trial of buprenorphine dosing regimens for opioid dependent youth</TI>
<SO>Proceedings of the 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence; 2011 June 18-23, Hollywood, Florida</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2014-03-28 11:23:27 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-04-28 11:42:56 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-04-28 11:42:56 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-AIHW-2011" MODIFIED="2014-04-03 10:23:52 +0200" MODIFIED_BY="[Empty name]" NAME="AIHW 2011" TYPE="OTHER">
<AU>Australian Institute of Health and Welfare (AIHW)</AU>
<TI>Drugs in Australia 2010: tobacco, alcohol and other drugs</TI>
<SO>Drug statistics series no. 27. Cat. no. PHE 154. Canberra</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altobelli-2005" MODIFIED="2014-04-25 12:59:56 +0200" MODIFIED_BY="Heather Maxwell" NAME="Altobelli 2005" TYPE="JOURNAL_ARTICLE">
<AU>Altobelli E, Rapacchietta L, Tiberti S, Petrocelli R, Cicioni L, di Orio F, et al</AU>
<TI>Association between drug, alcohol and tobacco use in adolescents and socio-familiar factors</TI>
<TO>Associazione tra l'uso di sostanze stupefacenti, alcol e tabacco negli adolescenti e contesto socio-familiare</TO>
<SO>Annali d'Igiene</SO>
<YR>2005</YR>
<VL>17</VL>
<PG>57-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Amato-2011" MODIFIED="2014-04-09 15:59:41 +0200" MODIFIED_BY="[Empty name]" NAME="Amato 2011" TYPE="COCHRANE_REVIEW">
<AU>Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S</AU>
<TI>Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2008-10-20 08:24:50 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-20 08:24:50 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005031"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Amato-2013" MODIFIED="2014-04-25 12:07:37 +0200" MODIFIED_BY="Heather Maxwell" NAME="Amato 2013" TYPE="COCHRANE_REVIEW">
<AU>Amato L, Davoli M, Minozzi S, Ferroni E, Ali R, Ferri M</AU>
<TI>Methadone at tapered doses for the management of opioid withdrawal</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-04-25 12:07:27 +0200" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2014-04-25 12:07:27 +0200" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD003409.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cochrane-Handboook-2008" MODIFIED="2014-04-25 13:00:46 +0200" MODIFIED_BY="Heather Maxwell" NAME="Cochrane Handboook 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]</TI>
<SO>The Cochrane Collaboration.. Available from www.cochrane-handbook.org</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Day-2005" MODIFIED="2008-10-20 08:27:23 +0200" MODIFIED_BY="[Empty name]" NAME="Day 2005" TYPE="COCHRANE_REVIEW">
<AU>Day E, Ison J, Strang J</AU>
<TI>Inpatient versus other settings for detoxification for opioid dependence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-10-20 08:27:23 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-20 08:27:23 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004580"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-EMCDDA-2012" MODIFIED="2014-04-03 10:24:23 +0200" MODIFIED_BY="[Empty name]" NAME="EMCDDA 2012" TYPE="OTHER">
<AU>European Monitoring Centre for Drugd &amp; Drug Addiction (EMCDDA)</AU>
<TI>Annual Report: The state of the drugs problem in Europe. European Union and Norway</TI>
<SO>Of&#64257;ce for publications of the European Communities, Luxembourg</SO>
<YR>2012</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ESPAD-2012" MODIFIED="2014-04-03 10:26:12 +0200" MODIFIED_BY="[Empty name]" NAME="ESPAD 2012" TYPE="OTHER">
<AU>Hibell B, Guttormsson U, Ahlström S, Balakireva O, Bjarnason T, Kokkevi A, et al</AU>
<TI>The 2011 ESPAD report: substance use among students in 36 European countries</TI>
<SO>Swedish Council for Information on Alcohol and Other Drugs, Stockholm, Sweden</SO>
<YR>2012</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gossop-1989" NAME="Gossop 1989" TYPE="JOURNAL_ARTICLE">
<AU>Gossop M, Green L, Phillips G, Bradley B</AU>
<TI>Lapse, relapse and survival among opiate addicts after treatment</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>154</VL>
<PG>348-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gowing-2009" MODIFIED="2014-04-25 12:04:05 +0200" MODIFIED_BY="Heather Maxwell" NAME="Gowing 2009" TYPE="COCHRANE_REVIEW">
<AU>Gowing L, Ali R, White J</AU>
<TI>Buprenorphine for the management of opioid withdrawal</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-04-25 12:00:49 +0200" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2014-04-25 12:00:49 +0200" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD002025.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gowing-2009b" MODIFIED="2014-04-28 11:40:00 +0200" MODIFIED_BY="[Empty name]" NAME="Gowing 2009b" TYPE="COCHRANE_REVIEW">
<AU>Gowing L, Ali R, White J</AU>
<TI>Opioid antagonists with minimal sedation for opioid withdrawal</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-04-25 12:03:11 +0200" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2014-04-25 12:03:11 +0200" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD002021.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gowing-2010" MODIFIED="2014-04-28 11:40:17 +0200" MODIFIED_BY="[Empty name]" NAME="Gowing 2010" TYPE="COCHRANE_REVIEW">
<AU>Gowing L, Ali R, White J</AU>
<TI>Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-04-25 12:10:34 +0200" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2014-04-25 12:10:34 +0200" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD002022.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gowing-2014" MODIFIED="2014-04-28 11:42:56 +0200" MODIFIED_BY="[Empty name]" NAME="Gowing 2014" TYPE="COCHRANE_REVIEW">
<AU>Gowing L, Farrell M, Ali R, White J</AU>
<TI>Alpha2-adrenergic agonists for the management of opioid withdrawal</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-04-25 12:13:44 +0200" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2014-04-25 12:13:44 +0200" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD002024.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hunt-1990" NAME="Hunt 1990" TYPE="JOURNAL_ARTICLE">
<AU>Hunt RD, Capper L, O'Connel P</AU>
<TI>Clonidine in child and adolescent psychiatry</TI>
<SO>Journal of Child Adolescent Psychofarmacology</SO>
<YR>1990</YR>
<VL>1</VL>
<PG>87-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaminer-1995" NAME="Kaminer 1995" TYPE="JOURNAL_ARTICLE">
<AU>Kaminer Y</AU>
<TI>Pharmacotherapy for adolescents with psychoactive substance use disorders</TI>
<SO>NIDA Research Monograph</SO>
<YR>1995</YR>
<VL>156</VL>
<PG>291-324</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kleber-1982" NAME="Kleber 1982" TYPE="JOURNAL_ARTICLE">
<AU>Kleber HD, Riordan CE</AU>
<TI>The treatment of narcotic withdrawal: a historical review</TI>
<SO>Journal of Clinical Psichiatry</SO>
<YR>1982</YR>
<VL>43</VL>
<NO>6</NO>
<PG>30-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levy-2007" MODIFIED="2014-04-28 11:40:25 +0200" MODIFIED_BY="[Empty name]" NAME="Levy 2007" TYPE="JOURNAL_ARTICLE">
<AU>Levy S, Vaughan BL, Angulo M, Knight JR</AU>
<TI>Buprenorphine replacement therapy for adolescents with opioid dependence: early experience from a children's hospital-based outpatient treatment program</TI>
<SO>Journal of Adolescent Health</SO>
<YR>2007</YR>
<VL>40</VL>
<NO>5</NO>
<PG>477-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lipton-1983" NAME="Lipton 1983" TYPE="JOURNAL_ARTICLE">
<AU>Lipton DS, Maranda MJ</AU>
<TI>Detoxification from heroin dependency: an overview of method and effectiveness</TI>
<SO>Advances in Alcohol and Substance Abuse</SO>
<YR>1983</YR>
<VL>2</VL>
<NO>1</NO>
<PG>31-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mattick-1996" NAME="Mattick 1996" TYPE="JOURNAL_ARTICLE">
<AU>Mattick RP, Hall W</AU>
<TI>Are detoxification programmes effective?</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>347</VL>
<PG>97-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Monitoring-the-Future-2013" MODIFIED="2014-04-03 10:27:24 +0200" MODIFIED_BY="[Empty name]" NAME="Monitoring the Future 2013" TYPE="OTHER">
<AU>Johnston LD, O&#8217;Malley PM, Bachman JG, Schulenberg JE</AU>
<TI>Monitoring the Future national results on drug use: 2012 Overview, Key Findings on Adolescent Drug Use</TI>
<SO>Ann Arbor: Institute for Social Research, The University of Michigan. 2013</SO>
<YR>2013</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SAMHSA-2013" MODIFIED="2014-04-03 10:27:54 +0200" MODIFIED_BY="[Empty name]" NAME="SAMHSA 2013" TYPE="OTHER">
<AU>Substance Abuse and Mental Health Services Administration (SAMHSA)</AU>
<TI>Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings</TI>
<SO>NSDUH Series H-46, HHS 2013;Publication No. (SMA) 13-4795. Rockville</SO>
<YR>2013</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2012" MODIFIED="2014-04-28 11:40:31 +0200" MODIFIED_BY="[Empty name]" NAME="Smith 2012" TYPE="JOURNAL_ARTICLE">
<AU>Smith B, Fagan J, Kernan K</AU>
<TI>Outcomes of heroin dependent adolescents presenting for opiate substitution treatment</TI>
<SO>Journal of Substance Abuse Treatment</SO>
<YR>2012</YR>
<VL>42</VL>
<NO>1</NO>
<PG>35-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vaillant-1988" MODIFIED="2009-01-27 01:34:33 +0100" MODIFIED_BY="Linda R. Gowing" NAME="Vaillant 1988" TYPE="JOURNAL_ARTICLE">
<AU>Vaillant GE</AU>
<TI>What can long-term follow-up teach us about relapse and prevention of relapse in addiction?</TI>
<SO>British Journal of Addiction</SO>
<YR>1988</YR>
<VL>83</VL>
<NO>10</NO>
<PG>1147-57</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-04-28 11:40:47 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Minozzi-2009" MODIFIED="2014-04-28 11:40:47 +0200" MODIFIED_BY="[Empty name]" NAME="Minozzi 2009" TYPE="COCHRANE_REVIEW">
<AU>Minozzi S, Amato L, Davoli M</AU>
<TI>Detoxification treatments for opiate dependent adolescents</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-04-25 11:55:35 +0200" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2014-04-25 11:55:35 +0200" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD006749.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-04-28 11:37:04 +0200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-04-28 11:37:04 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-04-28 11:35:54 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marsch-2005">
<CHAR_METHODS MODIFIED="2014-04-28 11:35:53 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial. Recruitment modality: self-referred participants.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-28 11:35:53 +0200" MODIFIED_BY="[Empty name]">
<P>36 adolescents (13-18 years) who met the DSM-IV criteria for opioid dependence. Pregnant women and patients with significant psychiatric disorders (e.g. psychosis) or medical illnesses (e.g. cardiovascular disease) were excluded.</P>
<P>Mean age. 17.35 years; 39% male; 97% white. Injection route of opiate use: 36%; other drug dependence alcohol: 17.5%, cannabis: 17%, cocaine: 10%, amphetamine: 6%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 11:35:54 +0200" MODIFIED_BY="[Empty name]">
<P>(1) Buprenorphine detoxification: sublingual buprenorphine tablets daily with flexible dosing procedure based on weight and self-reported opiate use at intake (starting dose range: 6 mg- 8 mg). Buprenorhine dose that decreased by 2 mg every 7 days. Behavioural therapy 3 one-hour individual sessions per week. Contingency management approach: participants could earn a voucher on the provision of opioid negative urine samples. At the end of the study, participants were offered naltrexone.</P>
<P>
<BR/>(2) Transdermal clonidine patches 0.1 mg on intake day and day 1; a second patch was added on day 2 and worn until day 6. An optional third patch (depending on the severity of withdrawal symptoms) may have been added on day 4 and worn until day 6. All patches were removed on day 7 and replaced with a 0.2 mg doses. On day 14 the patches were removed again and replaced with a 0.1 mg dose patch. On day 21 the patches were removed again and replaced with a 0 mg dose. Behavioural therapy 3 one-hour individual session per week. Contingency management approach: participants could earn a voucher on the provision of opioid negative urine samples. At the end of the study, participants were offered naltrexone.</P>
<P>
<BR/>Durattion of the trials: 28 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-28 11:35:54 +0200" MODIFIED_BY="[Empty name]">
<P>Drop out from treatment measured as the percentage of patients who did not complete the entire detoxification treatment. Time retained in treatment. Opiate abstinence as the percentage of scheduled urine samples opiate negative. Other drug use as percentage of urine samples positives. Acceptability of the treatment: withdrawal effect measured by the Adjective rating scale. Initiation of naltrexone treatment as percentage of patients who initiated.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-18 11:11:34 +0200" MODIFIED_BY="[Empty name]">
<P>Country: USA<BR/>Setting: outpatients</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-28 11:36:10 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Woody-2008">
<CHAR_METHODS MODIFIED="2014-04-28 11:36:10 +0200" MODIFIED_BY="[Empty name]">
<P>Multicentre randomised controlled trial. Recruitment modality described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-28 11:36:10 +0200" MODIFIED_BY="[Empty name]">
<P>154 participants who met the DSM IV diagnostic criteria for opioid dependence and who sought outpatient treatment.152 randomised. Mean age: 19 years. Only one participant was 15 years old and no participants were 14 years old. Male: 59%. White: 56%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 11:36:10 +0200" MODIFIED_BY="[Empty name]">
<P>(1) Maintenance group:12 weeks buprenorphine. Naloxone: up to 24 mg/day buprenorphine and 0.5 mg naloxone for 9 weeks and then tapered to week 12. :74 patients.</P>
<P>(2) Detoxification group: 2 weeks buprenorphine. Naloxone: up to 14 mg/day buprenorphine and then tapered to day 14: 78 patients.<BR/>
<BR/>
</P>
<P>Both groups were offered 1 weekly individual and 1 group counselling.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-28 11:36:10 +0200" MODIFIED_BY="[Empty name]">
<P>Primary outcome: opioid positive urine test results at weeks 4, 8 and 12.<BR/>
<BR/>
</P>
<P>Secondary outcomes: drop out, self-reported use, enrolment in addiction treatment outside the assigned condition, other drug use, adverse events. Results at 6,9,12 months follow-up: self-reported opioid use, self-reported other drug use, other addiction treatment received.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-28 11:36:10 +0200" MODIFIED_BY="[Empty name]">
<P>Country: USA</P>
<P>Setting: outpatients</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>DSM IV: Diagnostic and Statistical Manual of Mental Disorders, 4th edition<BR/>vs: versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-04-28 11:30:21 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-04-28 11:28:53 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baer-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 11:28:53 +0200" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria: only psychosocial intervention without pharmacological detoxification</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 11:28:57 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chakrabarti-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 11:28:57 +0200" MODIFIED_BY="[Empty name]">
<P>Outcome not in the inclusion criteria: baseline patient characteristics of <LINK REF="STD-Woody-2008" TYPE="STUDY">Woody 2008</LINK> trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 11:29:03 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ebner-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 11:29:03 +0200" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria: not RCT or CCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 11:29:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fiellin-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 11:29:07 +0200" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria: not RCT or CCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 11:29:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Forcehimes-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 11:29:13 +0200" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria: psychosocial intervention; the same pharmacological intervention given to both groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 11:29:20 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Godley-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 11:29:20 +0200" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria: not RCT or CCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 11:29:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hill-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 11:29:26 +0200" MODIFIED_BY="[Empty name]">
<P>Outcome not in the inclusion criteria: association between cannabis use during opioid dependence treatment and positive urine drug screens for opioids; no raw data about cannabis use in the two groups provided</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 11:29:36 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kemp-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 11:29:36 +0200" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria: only psychosocial intervention without pharmacological detoxification</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 11:29:41 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lehmann-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 11:29:41 +0200" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria: maintenance treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 11:29:45 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lloyd-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 11:29:45 +0200" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria: not RCT or CCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 11:29:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mannelli-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 11:29:48 +0200" MODIFIED_BY="[Empty name]">
<P>Participants not in the inclusion criteria: adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 11:29:55 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moore-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 11:29:55 +0200" MODIFIED_BY="[Empty name]">
<P>Secondary analysis of the all sample of the <LINK REF="STD-Marsch-2005" TYPE="STUDY">Marsch 2005</LINK> study without distinction between experimental and control condition</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 11:29:58 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moore-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 11:29:58 +0200" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria: qualitative study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 11:30:03 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mullen-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 11:30:03 +0200" MODIFIED_BY="[Empty name]">
<P>Study design and participants not in the inclusion criteria: observation cohort study on adult population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 11:30:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Polsky-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 11:30:06 +0200" MODIFIED_BY="[Empty name]">
<P>Outcome not in the inclusion criteria: cost effectiveness analysis of the <LINK REF="STD-Woody-2008" TYPE="STUDY">Woody 2008</LINK> trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 11:30:09 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Subramaniam-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 11:30:09 +0200" MODIFIED_BY="[Empty name]">
<P>Outcome not in the inclusion criteria: Predictors of Abstinence: secondary analysis of the <LINK REF="STD-Woody-2008" TYPE="STUDY">Woody 2008</LINK> trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 11:30:14 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Warden-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 11:30:14 +0200" MODIFIED_BY="[Empty name]">
<P>Outcome not in the inclusion criteria:Predictors of attrition: secondary analysis of the <LINK REF="STD-Woody-2008" TYPE="STUDY">Woody 2008</LINK> trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 11:30:18 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wilcox-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 11:30:18 +0200" MODIFIED_BY="[Empty name]">
<P>Outcome not in the inclusion criteria: Concordance between self-report and urine drug screen data: secondary analysis of the <LINK REF="STD-Woody-2008" TYPE="STUDY">Woody 2008</LINK> trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>CCT: controlledclinical trial<BR/>RCT: randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-04-28 11:30:27 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2014-04-28 11:30:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marsh-2009">
<CHAR_METHODS MODIFIED="2014-04-28 11:30:27 +0200" MODIFIED_BY="[Empty name]">
<P>Double blind randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-03 10:02:15 +0200" MODIFIED_BY="[Empty name]">
<P>53 opioid dependents adolescents and young adults (age 13-24 eligible)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 11:30:27 +0200" MODIFIED_BY="[Empty name]">
<P>Experimental: buprenorphine taper of 28 days</P>
<P>Control: buprenorphine taper of 63 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-28 11:30:27 +0200" MODIFIED_BY="[Empty name]">
<P>Retention in treatment; use of primary substance of abuse measured by urine analysis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-28 11:30:27 +0200" MODIFIED_BY="[Empty name]">
<P>Author contacted; study ended but definite results not yet published</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-03-28 11:23:27 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-04-28 11:36:20 +0200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-04-28 11:36:20 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 14:40:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marsch-2005">
<DESCRIPTION>
<P>"participants were randomly assigned to either detoxification with clonidine or with buprenorphine. In this process participants were stratified for sex and past month route of opiate use (injection vs intranasal)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 11:36:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Woody-2008">
<DESCRIPTION>
<P>Randomisation occurred through an automated 24-hour service at the Veterans Affairs Cooperative Studies Program in Perry Point, Maryland, that was programmed<BR/>to randomise patients separately by site. At each site, a biased coin randomisation protected against severe imbalance of sex, ethnicity, route of administration, and age across the treatment groups.</P>
<P>Age was dichotomised as 14 to 18 years or 18 to 21 years, ethnicity as the majority ethnic group vs all others within the site, and route of administration as injecting or non injecting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-04-25 14:26:12 +0200" MODIFIED_BY="Heather Maxwell" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 14:40:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marsch-2005">
<DESCRIPTION>
<P>"participants were randomly assigned to either detoxification with clonidine or with buprenorphine. In this process participants were stratified for sex and past month route of opiate use (injection vs intranasal)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-25 14:26:12 +0200" MODIFIED_BY="Heather Maxwell" RESULT="NO" STUDY_ID="STD-Woody-2008">
<DESCRIPTION>
<P>Balance was assessed by comparing the group sum of the binary indicators as each new patient was randomised. If both groups were balanced when a new patient was being randomised, then each group had an allocation probability of 1/2; if there was an imbalance, then the group with the higher score on the sum of indicators received an allocation probability of 1/3 and the other group a probability of 2/3.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-04-28 11:36:20 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>objective outcomes (drop out, use of substance measured by urine-analysis, abstinent at follow-up, initiation of naltrexone treatment)</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>Subjective outcome</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-04-25 14:18:30 +0200" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Marsch-2005">
<DESCRIPTION>
<P>"The study used a parallel group, double blind, double dummy design". Participants in the clonidine group received placebo buprenorphine tablets and patients in the buprenorphine group received placebo clonidine patches"<BR/>
<BR/>COMMENT: the outcomes are unlikely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2014-04-28 11:36:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marsch-2005">
<DESCRIPTION>
<P>"The study used a parallel group, double blind, double dummy design". Participants in the clonidine group received placebo buprenorphine tablets and patients in the buprenorphine group received placebo clonidine patches"<BR/>COMMENT: blinding of participants and personnel. Not specified if research staff members who assessed subjective outcomes were blind but we judge that they probably were.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-04-28 11:36:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Woody-2008">
<DESCRIPTION>
<P>Patients and providers impossible to be blinded for the nature of the intervention (14 days detox vs 12 weeks maintenance).</P>
<P>COMMENT: objective outcomes unlikely to be biased by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2014-04-28 11:36:20 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Woody-2008">
<DESCRIPTION>
<P>Patients and providers impossible to be blinded for the nature of the intervention (14 days detox vs 12 weeks maintenance)</P>
<P>Outcome assessor not blinded: "Research assistant likely knew groups assignment because the study was not blinded"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-04-28 11:36:20 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-26 16:59:47 +0200" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Marsch-2005">
<DESCRIPTION>
<P>"the primary analysis (drop out, time retained, use of substance) included all participants randomised independently to drop out/non compliance, consistent with an intention to treat approach. All secondary outcomes (withdrawals symptoms and signs) were confined to the data from treatment intake to the end of the first week when retention was still high in both condition"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-28 11:36:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Woody-2008">
<DESCRIPTION>
<P>Number of participants withdrawn from the study reported for each group. Reason for withdrawal given. Analysis on the basis of the Intention-to-treat principle: "patients were contacted at all assessment point regardless of whether they remained in treatment".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-04-28 11:36:20 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 11:36:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marsch-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 11:36:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Woody-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2008-10-18 11:21:53 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-04-28 11:33:28 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;b&gt;H Maxwell:&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Summary of findings&lt;br&gt;Settings: &lt;/b&gt;Not listed for either table.&lt;b&gt;&lt;br&gt;Footnotes: &lt;/b&gt;No comment for footnote number 4 in Table 2.&lt;/p&gt;" NOTES_MODIFIED="2014-04-28 11:33:28 +0200" NOTES_MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-04-28 11:33:02 +0200" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2014-04-28 11:32:24 +0200" MODIFIED_BY="[Empty name]">Buprenorphine versus clonidine for opiate dependent adolescents</TITLE>
<TABLE COLS="7" ROWS="16">
<TR>
<TD COLSPAN="7">
<P>
<B>Buprenorphine versus clonidine for opiate dependent adolescents</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with opiate dependent adolescents<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> buprenorphine versus clonidine<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Buprenorphine versus clonidine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Drop out</B>
<BR/>Number of participants who did not complete the detoxification treatment<BR/>Follow-up: 28 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.45 </B>
<BR/>(0.2 to 1.04)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>36<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>611 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>275 per 1000</B>
<BR/>(122 to 636)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>611 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>275 per 1000</B>
<BR/>(122 to 635)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Duration and severity of signs and symptoms of withdrawal</B>
<BR/>Adjective rating scale<BR/>Follow-up: 28 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean duration and severity of signs and symptoms of withdrawal in the control groups was<BR/>
<B>-18.8 score</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean duration and severity of signs and symptoms of withdrawal in the intervention groups was<BR/>
<B>3.97 higher</B>
<BR/>(1.38 lower to 9.32 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>32<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Initiation of naltrexone treatment</B>
<BR/>Number of participants initiating naltrexone<BR/>Follow-up: 28 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 11 </B>
<BR/>(1.58 to 76.55)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>36<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>56 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>611 per 1000</B>
<BR/>(88 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>56 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>616 per 1000</B>
<BR/>(88 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> only one study included<BR/>
<SUP>2</SUP> only one study with 36 participants included</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2014-04-28 11:33:28 +0200" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2014-04-28 11:33:13 +0200" MODIFIED_BY="[Empty name]">Buprenorphine detox compared with buprenorphine maintenance for opiate dependent adolescents</TITLE>
<TABLE COLS="7" ROWS="23">
<TR>
<TD COLSPAN="7">
<P>
<B>Buprenorphine detox compared with buprenorphine maintenance for opiate dependent adolescents</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with opiate dependent adolescents<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> buprenorphine detox<BR/>
<B>Comparison: </B>buprenorphine maintenance</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Buprenorphine maintenance</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Buprenorphine detox</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Drop out</B>
<BR/>Number of participants who dropped out from the study<BR/>
<BR/>Follow-up: 12 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 2.67 </B>
<BR/>(1.85 to 3.86)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>152<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>297 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>794 per 1000</B>
<BR/>(550 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>297 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>793 per 1000</B>
<BR/>(549 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Patients with positive urine at the end of treatment</B>
<BR/>Number of participants with urine positive for opiates<BR/>
<BR/>Follow-up: 12 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.03 </B>
<BR/>(0.82 to 1.28)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>152<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>662 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>682 per 1000</B>
<BR/>(543 to 848)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>662 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>682 per 1000</B>
<BR/>(543 to 847)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Self-reported use at 12 months follow-up</B>
<BR/>Number of participants who reported heroin used at follow-up<BR/>
<BR/>Follow-up: 12 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.36 </B>
<BR/>(1.05 to 1.76)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>152<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>527 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>717 per 1000</B>
<BR/>(553 to 928)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>527 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>717 per 1000</B>
<BR/>(553 to 928)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Enrolment in addiction treatment at 12 month follow-up</B>
<BR/>Number of participants enrolled in addiction treatment at follow-up<BR/>
<BR/>Follow-up: 12 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.75 </B>
<BR/>(0.53 to 1.07)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>152<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>527 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>395 per 1000</B>
<BR/>(279 to 564)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>527 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>395 per 1000</B>
<BR/>(279 to 564)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> no allocation concealment<BR/>
<SUP>2</SUP> only one study with 154 participants<BR/>
<SUP>3</SUP> participants, providers and outcome assessor not blinded<BR/>
<SUP>4</SUP> </P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-04-28 11:42:50 +0200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-04-28 11:41:07 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Buprenorphine versus clonidine</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0435393630469627" CI_START="0.19799116120034246" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" I2="0.0" I2_Q="100.0" ID="CMP-001.01" LOG_CI_END="0.01850883560718636" LOG_CI_START="-0.7033541972515989" LOG_EFFECT_SIZE="-0.3424226808222062" METHOD="MH" MODIFIED="2008-10-18 11:33:16 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.0629625900673506" Q="6.855445015526699E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.00000000000001" Z="1.8594555791097556">
<NAME>drop out</NAME>
<GROUP_LABEL_1>buprenorphine</GROUP_LABEL_1>
<GROUP_LABEL_2>clonidine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0435393630469627" CI_START="0.19799116120034246" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.01850883560718636" LOG_CI_START="-0.7033541972515989" LOG_EFFECT_SIZE="-0.3424226808222062" MODIFIED="2008-10-18 11:33:16 +0200" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.4240259187808922" STUDY_ID="STD-Marsch-2005" TOTAL_1="18" TOTAL_2="18" VAR="0.1797979797979798" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.32285953635164" CI_START="-1.3828595363516376" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.9700000000000006" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2008-10-18 11:34:13 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.14604996112886498" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="99.99999999999999" Z="1.4536262283331594">
<NAME>withdrawal score</NAME>
<GROUP_LABEL_1>buprenorphine</GROUP_LABEL_1>
<GROUP_LABEL_2>clonidine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.32285953635164" CI_START="-1.3828595363516376" EFFECT_SIZE="3.9700000000000006" ESTIMABLE="YES" MEAN_1="-14.83" MEAN_2="-18.8" MODIFIED="2008-10-18 11:34:13 +0200" MODIFIED_BY="[Empty name]" ORDER="5" SD_1="7.45" SD_2="7.99" SE="2.7311009684740695" STUDY_ID="STD-Marsch-2005" TOTAL_1="16" TOTAL_2="16" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="76.55126372499763" CI_START="1.5806401372377064" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="1.8839523645217129" LOG_CI_START="0.19883300579473764" LOG_EFFECT_SIZE="1.0413926851582251" METHOD="MH" MODIFIED="2008-10-18 11:34:52 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.015414562143118399" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0" Z="2.4224897139814785">
<NAME>initiation of naltrexone treatment</NAME>
<GROUP_LABEL_1>buprenorphine</GROUP_LABEL_1>
<GROUP_LABEL_2>clonidine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="76.55126372499755" CI_START="1.5806401372377066" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.8839523645217124" LOG_CI_START="0.1988330057947377" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2008-10-18 11:34:52 +0200" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.9898474527915803" STUDY_ID="STD-Marsch-2005" TOTAL_1="18" TOTAL_2="18" VAR="0.9797979797979797" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-04-28 11:42:50 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Buprenorphine detox versus buprenorphine maintenance</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.8629408376418803" CI_START="1.8505217529859201" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.6736596736596736" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="22" I2="0.0" I2_Q="100.0" ID="CMP-002.01" LOG_CI_END="0.5869180568162098" LOG_CI_START="0.2672941946168769" LOG_EFFECT_SIZE="0.42710612571654344" METHOD="MH" MODIFIED="2009-02-05 15:55:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="1.622285425177468E-7" Q="3.496768373502511E-31" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="74" WEIGHT="100.00000000000001" Z="5.238110935902513">
<NAME>drop out</NAME>
<GROUP_LABEL_1>detox</GROUP_LABEL_1>
<GROUP_LABEL_2>maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.8629408376418803" CI_START="1.8505217529859201" EFFECT_SIZE="2.6736596736596736" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="22" LOG_CI_END="0.5869180568162098" LOG_CI_START="0.2672941946168769" LOG_EFFECT_SIZE="0.42710612571654344" MODIFIED="2009-02-05 15:55:24 +0100" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.18774863881952283" STUDY_ID="STD-Woody-2008" TOTAL_1="78" TOTAL_2="74" VAR="0.03524955137858364" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2824850235055367" CI_START="0.8210725081958274" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0261643118785977" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="49" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.1080523022463251" LOG_CI_START="-0.08561848902078274" LOG_EFFECT_SIZE="0.011216906612771216" METHOD="MH" MODIFIED="2009-02-06 12:07:36 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.8203988640692126" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="74" WEIGHT="100.0" Z="0.22703199419121226">
<NAME>patients with positive urine at the end of treatment</NAME>
<GROUP_LABEL_1>detox</GROUP_LABEL_1>
<GROUP_LABEL_2>maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2824850235055367" CI_START="0.8210725081958276" EFFECT_SIZE="1.0261643118785977" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="49" LOG_CI_END="0.1080523022463251" LOG_CI_START="-0.08561848902078267" LOG_EFFECT_SIZE="0.011216906612771216" MODIFIED="2009-02-06 12:07:36 +0100" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="0.1137631814761774" STUDY_ID="STD-Woody-2008" TOTAL_1="78" TOTAL_2="74" VAR="0.012942061459581673" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7610761971935207" CI_START="1.053762954938102" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3622616699539776" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.24577814716816807" LOG_CI_START="0.022742926872225948" LOG_EFFECT_SIZE="0.13426053702019697" METHOD="MH" MODIFIED="2014-04-28 11:42:05 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.018290730317965968" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="74" WEIGHT="99.99999999999999" Z="2.359679486992489">
<NAME>self-reported use at 12 months follow-
up</NAME>
<GROUP_LABEL_1>detox</GROUP_LABEL_1>
<GROUP_LABEL_2>maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7610761971935207" CI_START="1.053762954938102" EFFECT_SIZE="1.3622616699539776" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="39" LOG_CI_END="0.24577814716816807" LOG_CI_START="0.022742926872225948" LOG_EFFECT_SIZE="0.13426053702019697" MODIFIED="2009-02-06 12:26:37 +0100" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="0.13101199244398262" STUDY_ID="STD-Woody-2008" TOTAL_1="78" TOTAL_2="74" VAR="0.017164142164142162" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0682267100463612" CI_START="0.5323594586800414" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7541091387245233" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.0286634329110821" LOG_CI_START="-0.2737950252145436" LOG_EFFECT_SIZE="-0.12256579615173073" METHOD="MH" MODIFIED="2014-04-28 11:42:18 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.11217792907805883" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="74" WEIGHT="99.99999999999999" Z="1.5884796059767867">
<NAME>enrolment in addiction treatment at 12-month follow-up</NAME>
<GROUP_LABEL_1>detox</GROUP_LABEL_1>
<GROUP_LABEL_2>maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours maintenence</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours detox</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0682267100463612" CI_START="0.5323594586800414" EFFECT_SIZE="0.7541091387245233" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="39" LOG_CI_END="0.0286634329110821" LOG_CI_START="-0.2737950252145436" LOG_EFFECT_SIZE="-0.12256579615173073" MODIFIED="2014-04-09 15:12:06 +0200" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.17766559549650668" STUDY_ID="STD-Woody-2008" TOTAL_1="78" TOTAL_2="74" VAR="0.031565063823128334" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.020317319674574" CI_START="0.6282346466479415" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.126602564102564" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.30541958695185734" LOG_CI_START="-0.20187811627705737" LOG_EFFECT_SIZE="0.05177073533739997" METHOD="MH" MODIFIED="2014-04-28 11:42:25 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.689129698440964" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="74" WEIGHT="100.0" Z="0.40003641281487107">
<NAME>self-reported alcohol use</NAME>
<GROUP_LABEL_1>detox</GROUP_LABEL_1>
<GROUP_LABEL_2>maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.020317319674574" CI_START="0.6282346466479414" EFFECT_SIZE="1.126602564102564" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.30541958695185734" LOG_CI_START="-0.20187811627705746" LOG_EFFECT_SIZE="0.05177073533739997" MODIFIED="2009-02-06 12:30:07 +0100" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="0.29798918204079505" STUDY_ID="STD-Woody-2008" TOTAL_1="78" TOTAL_2="74" VAR="0.08879755261334209" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.0020661873563603" CI_START="0.8328206216497291" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5811965811965811" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.47742026301943163" LOG_CI_START="-0.07944852970572738" LOG_EFFECT_SIZE="0.19898586665685214" METHOD="MH" MODIFIED="2014-04-28 11:42:33 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.16130157530785846" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="74" WEIGHT="100.0" Z="1.4007074455415056">
<NAME>self-reported marijuana use</NAME>
<GROUP_LABEL_1>detox</GROUP_LABEL_1>
<GROUP_LABEL_2>maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.0020661873563603" CI_START="0.8328206216497291" EFFECT_SIZE="1.5811965811965811" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="12" LOG_CI_END="0.47742026301943163" LOG_CI_START="-0.07944852970572738" LOG_EFFECT_SIZE="0.19898586665685214" MODIFIED="2009-02-06 12:32:42 +0100" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.3271074853917394" STUDY_ID="STD-Woody-2008" TOTAL_1="78" TOTAL_2="74" VAR="0.106999306999307" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="65.75494839345477" CI_START="1.1087427976910094" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="8.538461538461538" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="1.81792844125466" LOG_CI_START="0.0448308117049815" LOG_EFFECT_SIZE="0.9313796264798206" METHOD="MH" MODIFIED="2014-04-28 11:42:50 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.03948705183484599" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="74" WEIGHT="100.0" Z="2.0590750260023074">
<NAME>self-reported cocaine use</NAME>
<GROUP_LABEL_1>detox</GROUP_LABEL_1>
<GROUP_LABEL_2>maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="65.75494839345477" CI_START="1.1087427976910094" EFFECT_SIZE="8.538461538461538" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.81792844125466" LOG_CI_START="0.0448308117049815" LOG_EFFECT_SIZE="0.9313796264798206" MODIFIED="2009-02-06 12:35:03 +0100" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="1.0415263245723003" STUDY_ID="STD-Woody-2008" TOTAL_1="78" TOTAL_2="74" VAR="1.0847770847770848" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-04-28 11:36:21 +0200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="figura 01 flow chart.ppt adolescents.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2014-04-25 15:00:23 +0200" MODIFIED_BY="Heather Maxwell" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>

Flow chart of studies of the review published in 2009</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-04-25 12:26:45 +0200" MODIFIED_BY="Heather Maxwell" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram. 2014 update</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAoIAAANBCAYAAAB0+9+7AABy60lEQVR42uydAURf3///v8zHZGZG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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-04-28 11:36:21 +0200" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAABPsAAADnCAMAAABfYaP2AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2014-04-28 11:36:21 +0200" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAARQAAAQuCAIAAACSy1VCAAAb2UlEQVR42u3dvY4dSRXA8ZGQEIED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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-04-02 11:06:32 +0200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-10-27 11:50:34 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-10-17 17:34:29 +0200" MODIFIED_BY="[Empty name]">Cochrane Drugs and Alcohol Group's trials register search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-27 11:50:34 +0100" MODIFIED_BY="[Empty name]">
<P>Free text=detox* or withdraw* or abstinen* or abstain* AND Diagnosis = opiate* or opioid* <BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-04-02 11:06:32 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2014-04-02 11:05:33 +0200" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-04-02 11:06:32 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>MeSH descriptor: [Opioid-Related Disorders] explode all trees</LI>
<LI>((drug or substance) near (abuse* or addict* or dependen* or disorder*)):ti,ab,kw (Word variations have been searched)</LI>
<LI>((opioid* or opiate*) near (abuse* or addict* or dependen*)):ti,ab,kw (Word variations have been searched)</LI>
<LI>(detox* or desintoxi* or disintoxi*):ti,ab,kw</LI>
<LI>#1 or #2 or #3 or #4</LI>
<LI>MeSH descriptor: [Heroin] explode all trees</LI>
<LI>(opioid* or opiate* or opium or heroin):ti,ab,kw (Word variations have been searched)</LI>
<LI>MeSH descriptor: [Methadone] explode all trees</LI>
<LI>"methadone":ti,ab,kw (Word variations have been searched)</LI>
<LI>#6 or #7 or #8 or #9</LI>
<LI>#5 AND #10</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-04-02 11:05:46 +0200" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2008-10-27 11:33:12 +0100" MODIFIED_BY="[Empty name]">PubMed search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-04-01 13:35:50 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>"Opioid-Related Disorders"[MeSH]</LI>
<LI>(detox*[tiab] OR withdraw*[tiab] OR abstinen*[tiab] OR abstain*[tiab])</LI>
<LI>(opioid*[tiab] AND (abuse*[tiab] OR addict*[tiab] OR dependen*[tiab]))</LI>
<LI>((drug[tiab] OR substance[tiab]) AND (use*[tiab] OR abuse*[tiab] OR misuse*[tiab] OR addict*[tiab] OR dependen*[tiab] OR disorder*[tiab]))</LI>
<LI>#1 OR #2 OR #3 OR #4</LI>
<LI>heroin [MeSH]</LI>
<LI>heroin [tiab]</LI>
<LI>opioid*[tiab] OR opiate* [tiab]</LI>
<LI>methadone [MeSH]</LI>
<LI>methadone [MeSH]</LI>
<LI>#6 OR #7 OR #8 OR #9 OR #10</LI>
<LI>adolescent [MeSH]</LI>
<LI>adolescen* OR teen* OR young people OR young person* OR young adult* OR youth* OR girl* OR boy* OR juvenile*</LI>
<LI>#12 OR #13</LI>
<LI>randomized controlled trial [pt]</LI>
<LI>controlled clinical trial [pt]</LI>
<LI>random*[tiab]</LI>
<LI>placebo [tiab]</LI>
<LI>drug therapy [sh]</LI>
<LI>randomly [tiab]</LI>
<LI>trials [tiab]</LI>
<LI>groups [tiab]</LI>
<LI>#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22</LI>
<LI>animals [mh] NOT humans [mh]</LI>
<LI>#23 NOT #24</LI>
<LI>#5 AND #11 AND #14 AND #25</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-04-02 11:05:44 +0200" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2008-10-17 17:35:27 +0200" MODIFIED_BY="[Empty name]">Embase search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-04-01 13:35:19 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>drug abuse/exp</LI>
<LI>addiction/exp</LI>
<LI>((drug OR substance) NEAR/5 (abuse* OR depend* OR addict*)):ab,ti</LI>
<LI>detox*:ab,ti OR withdraw*:ab,ti OR abstinen*:ab,ti OR abstain*:ab,ti</LI>
<LI>#1 or #2 or #3 or #4</LI>
<LI>'diamorphine'/exp</LI>
<LI>'methadone'/exp</LI>
<LI>heroin:ab,ti OR methadone:ab,ti OR opioid*:ab,ti OR opiate*:ab,ti</LI>
<LI>#6 or #7 or #8 or 9</LI>
<LI>'adolescent'/exp OR adolescen*:ab,ti OR teen*:ab,ti OR youth*:ab,ti OR girl$*:ab,ti OR boy*:ab,ti OR juvenile*:ab,ti OR (young NEAR/3 people):ab,ti OR (young NEAR/3 person*):ab,ti OR (young NEAR/3 adult*):ab,ti</LI>
<LI>'crossover procedure'/exp OR 'double blind procedure'/exp OR 'single blind procedure'/exp OR 'controlled clinical trial'/exp OR 'clinical trial'/exp OR 'randomized controlled trial'/exp OR placebo:ab,ti OR 'double blind':ab,ti OR 'single blind':ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR volunteer*:ab,ti OR random*:ab,ti OR factorial*:ab,ti OR crossover:ab,ti OR (cross:ab,ti AND over:ab,ti)</LI>
<LI>#5 AND #9 AND #10 AND #11AND [embase]/lim </LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2014-04-02 11:05:40 +0200" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2008-10-27 11:45:51 +0100" MODIFIED_BY="[Empty name]">CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-04-02 09:46:58 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>(MH "Substance Use Disorders+")</LI>
<LI>TX(detox* or withdraw* or abstinen* or abstain*)</LI>
<LI>TX((opioid* or opiate*) and (abuse* or addict* or dependen*))</LI>
<LI>S1 or S2 or S3</LI>
<LI>MH heroin or TX heroin</LI>
<LI>TX (opioid* or opiate*)</LI>
<LI>TX opium</LI>
<LI>MH methadone or  TX methadone</LI>
<LI>S5 or S6 or S7 or S8</LI>
<LI>MH adolescence</LI>
<LI>TI adolescen* or TI teen* or TI young people or TI young person* or TI young adult* or TI youth* or TI girl* OR TIboy* or TI juvenile*</LI>
<LI>AB adolescen* or AB teen* or AB young people or AB young person* or AB young adult* or AB youth* or AB girl* OR AB boy* or AB juvenile*</LI>
<LI>S10 or S11 or S12</LI>
<LI>MH "Clinical Trials+"</LI>
<LI>PT Clinical trial</LI>
<LI>TI clinic* N1 trial* or AB clinic* N1 trial*</LI>
<LI>TI ( singl* or doubl* or trebl* or tripl* ) and TI ( blind* or mask* )</LI>
<LI>AB ( singl* or doubl* or trebl* or tripl* ) and AB ( blind* or mask* )</LI>
<LI>TI randomi?ed control* trial* or AB randomi?ed control* trial*</LI>
<LI>MH "Random Assignment"</LI>
<LI>TI random* allocat* or AB random* allocat*</LI>
<LI>MH "Placebos"</LI>
<LI>TI placebo* or AB placebo*</LI>
<LI>MH "Quantitative Studies"</LI>
<LI>S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22 or S23 or S24</LI>
<LI>S4 and S9 and S13 and S25</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2014-04-02 11:05:37 +0200" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2014-04-02 08:46:13 +0200" MODIFIED_BY="[Empty name]">Web of Science search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-04-02 08:47:49 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>TS=((( heroin OR opiate* OR opioid* OR methadone) same (abuse* OR depend* OR addict* OR disorder* OR detox* OR withdraw* OR abstinen* OR abstain*))) AND TS=(adolescen* OR teen* OR young people OR young person* OR young adult* OR early adult* OR youth* OR girl* OR boy* OR juvenile*)</LI>
<LI>TS= clinical trial* OR TS=research design OR TS=comparative stud* OR TS=evaluation stud* OR TS=controlled trial* OR TS=follow-up stud* OR TS=prospective stud* OR TS=random* OR TS=placebo* OR TS=(single blind*) OR TS=(double blind*)</LI>
<LI>#2 AND #1</LI>
</OL>
<P>
<I>Databases=SCI-EXPANDED, SSCI, A&amp;HCI Timespan=2008-2013</I>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_2" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="2">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;2 studies included in qualitative synthesis (4 reports: 2 errata corrige of already included study, 2 conference proceeding related to one awaiting assessment new study)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;2 studies included in previous version of review&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;15 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1004 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1004 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;1164 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;986 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;11 full-text articles excluded, with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>